Sertralina

Zoloft, Tatig e altri

Bibliografia - Quali fonti bibliografiche per Sertralina?

1. Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.


2. Alwan S. et al., NEJM, 2007, 356, 2684.


3. Bandelow B. et al., J. Clin. Psychiatry, 2004, 65 (3), 405.


4. Boer R.A. et al., BMC Emergency Medicine, 2005, 5, 5.


5. Carson H.J. et al., Am. J. Forensic Med. Pathol., 2000, 21, 273.


6. Casper R.C. et al., J. Pediatr., 2003, 142, 402.


7. Chambers C.D. et al., NEJM, 2006, 354, 579.


8. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.


9. De Abajo F.J. et al., BMJ, 1999, 319, 1106.


10. Doogan D.P., Caillard V., Br. J. Psychiatry, 1992, 160, 217.


11. Drug Ther. Bull., 1991, 4 (13), 51.


12. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.


13. Fisekonc' S., Loga-Zec S., Bosn. J. Basic Med. Sci., 2005, 5 (2), 78.


14. Glassman A.H. et al., JAMA, 2002, 288, 701.


15. Gulseren L. et al., Arch. Med. Res., 2005, 36 (2), 159.


16. Hoechns J.D. et al., Ann. Pharmacother., 2001, 35, 862.


17. Kmijima K. et al., Int. Clin. Psychopharmacol., 2005, 20 5), 265.


18. Kirby D. et al., Internet J. Ger. Psychiatry, 2002, 17, 231.


19. Jureidini J.N. et al., BMJ, 2004, 328, 879.


20. Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.


21. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.


22. Louik C. et al., NEJM, 2007, 356, 2675.


23. Malm H. et al., Obstet. Gynecol., 2005, 106, 1289.


24. Markowitz J.S., DeVane C.L., J. Clin. Psychopharmacol., 2000, 20, 109.


25. Mason P.J. et al., Medicine, 2000, 79, 201.


26. Mills J.L., NEJM, 2006, 354, 636.


27. Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.


28. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.


29. Murdock D., McTavish D., Drugs, 1992, 44 (4), 604.


30. Nace D.A., Towers A., J. Am. Ger. Soc., 1999, 47, S32.


31. NICE – National Institute for Health and Clinical Excellence, 2007, disponibile online www.nice.org.uk/nicemedia/pdf/CG23fullguideline.pdf


32. Nielsen J.A. et al., Am. J. Clin. Nutr., 1992, 55, 185S.


33. Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.


34. Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.


35. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.


36. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.


37. Rey J. et al., Rheumatology, 2003, 42, 601.


38. Sansone R.A., Sansone L.A., Int. J. Psychiatry Med., 2003, 33 (1), 103.


39. Serebruany V.L., Am. J. Med., 2006, 119, 113.


40. Stone Z.N. et al., Am. J. Psychiatry, 1997, 154, 1255.


41. Trenque T. et al., Pharmacoepidemiol. Drug Safety, 2002, 11, 281.


42. van Walraven C. et al., BMJ, 2001, 323, 655.


43. Yonkers K.A. et al., JAMA, 1997, 278, 983.


44. Wagner K.D. et al., JAMA, 2003, 290, 1033.


45. Walkup J.T. et al., NEJM, 2008, 359, 2753.


46. Warrington S.J., Int. Clin. Psychopharmacol., 1991, 6 (Suppl. 2), 11.


47. Weissman A.M. et al., Am. J. Psychiatry, 2004, 161, 1066.


48. Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.


49. Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.